Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

xtension rapidly showed significant improvement in memory and cognition, while AC-1202 appeared to have a disease stabilizing effect on subjects expressing the ApoE4 genotype (ApoE4(-)). Regardless of genotype, all subjects who remained on AC- 1202 for all nine months of the study showed very little disease progression, declining only 0.8 points below baseline in ADAS-Cog scores in contrast to the 5.4-point decline observed in placebo subjects extrapolated to nine months.

"The significant and rapid cognitive improvements observed in ApoE4(-) patients support the efficacy observed in our Phase IIa study," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and neuronal hypometabolism," she added, referring to AC-1202's novel mechanism of action.

AC-1202 continued to be well tolerated by subjects in the open-label extension study, providing an additional six months of safety data. The incidence of treatment-related gastrointestinal side effects was similar to that of other AD drugs in the double-blind phase of the study, but a reformulated version of AC-1202 used in the open-label extension study greatly reduced these side effects.

"The excellent safety profile of AC-1202 in addition to its efficacy on top of existing AD drugs makes it a strong candidate for a co-therapeutic approach to the treatment of Alzheimer's disease," said Dr. Steve Orndorff.

Open-label results were highlighted in a "Late Breaking News" press conference today at 1:30 p.m. (EDT) by the Alzheimer's Association. The 2nd Annual International Conference on Prevention of Dementia, a multidisciplinary forum for professionals from the fields of bench research, drug discovery, medicine, care and public policy, is hosted by the Alzheimer's Association, the leading voluntary health organization in Alzheimer care, support and research.

About AC-1202

Brain imaging tec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/27/2014)... and MENLO PARK, Calif. , Aug. ... DMPI), developer of advanced cancer therapeutics , will ... Annual Rodman & Renshaw Global Investment Conference, sponsored by ... take place Tuesday, September 9th at 2:55 p.m. EDT ... New York Palace Hotel in New York ...
(Date:8/27/2014)... 2014 About 8 million Americans have peripheral ... of fatty plaque in the arteries, according to recent ... and in incidences of diabetes and obesity, the ... Extremity Arterial RevascularizatioN (LEARN) meeting, Oct. 9–11 in ... interested residents and fellows will be able to gain ...
(Date:8/27/2014)... Research and Markets  has announced the addition of ... report to their offering. The Global ... in-depth study on the current state of the global ... basic overview of the industry including definitions, classifications, applications ... is provided for the international markets including development trends, ...
Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3Global Pulse Oximeter Industry Report 2014 2
... from Biodel Inc. (Nasdaq: BIOD ) reported ... basal insulin and stabilized glucagon development programs in poster ... Technology Meeting in Bethesda, MD.   Dr. ... double-blind, randomized crossover trial in 13 subjects with type ...
... (NYSE Amex: NBS ) ("NeoStem" or the ... revenues, global research and development capabilities and operations in ... adult stem cells, and China pharmaceuticals, is today providing ... Third Quarter Results Revenues for the nine ...
Cached Medicine Technology:Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 2Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 3Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 4Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 5NeoStem Provides Third Quarter Update 2NeoStem Provides Third Quarter Update 3
(Date:8/27/2014)... Ticket Down is a dependable ... Levi’s Stadium in Santa Clara. Levi’s Stadium is a ... opened in July and will host their first international soccer ... These are two of the best teams that are both ... will look to continue their successes from the tournament in ...
(Date:8/27/2014)... Texas (PRWEB) August 28, 2014 BRIC ... Outlook to 2020?, provides key market data on the ... of US dollars, volume (in units) and average prices ... Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), Robotic ... are a number of advantages to the patient with ...
(Date:8/27/2014)... August 27, 2014 Michigan Head & Neck ... children of a local elementary school by ensuring they have ... School has year-round attendance, and Michigan Head & Neck Institute ... the new school year. , "There are a lot of ... a great way to give back to our community," said ...
(Date:8/27/2014)... role in inflaming blood vessels and hardening arteries, which ... demonstrates that they may also contribute to pulmonary hypertension, ... vessels in the lungs. , Using a rodent model, ... the main protein in high-density lipoprotein (HDL), the so-called ... lipids in pulmonary hypertension. They also found that reducing ...
(Date:8/27/2014)... Sound Telecom, a leading telecommunications company that offers ... systems, has unveiled an article titled “ Three Things ... .” The piece examines the world of medical messaging ... compliant with HIPAA and HITECH requirements. , Brian ... Sound Telecom, opens with evidence that the use of ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3
... Since mephedrone was made illegal in the UK in 2010, the ... degraded, which in turn may have reduced use of the drug. ... continued to use mephedrone after it became illegal would switch to ... by their friends or on the Internet. They would be ...
... health records (EHRs) are rapidly becoming part of the ... of care. In the first large study of its ... Nursing determined that nurses working with EHRs consistently reported ... for patients than nurses working in hospitals without this ...
... , TUESDAY, Jan. 17 (HealthDay News) -- With the Alzheimer,s ... ages, a panel of experts is meeting for two days ... fast emerging as one of the nation,s biggest -- and ... is to improve diagnosis, buttress support and training programs for ...
... drug called regorafenib slowed the progression of tumors and lengthened ... an international phase III clinical trial found. The findings were ... American Society of Clinical Oncology in San Francisco by ... principal investigator of the trial in the United States. ...
... are performed on all newborns born in the U.S. ... are not apparent at birth. These newborn screening programs ... early and improve outcomes in potentially devastating conditions. ... the data collection linked to newborn screening results, aiming ...
... Jan. 16, 2012 Listen up, pedestrians wearing headphones. ... Many probably can,t, especially young adult males. Serious ... in six years, according to new research from the University ... Medical Center in Baltimore. In many cases, the cars ...
Cached Medicine News:Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 3Health News:Drug improves survival of colorectal cancer patients, trial results show 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 3Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 2Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 3
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: